Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy
Alexandre Guérémy(Hôpital de la Timone), Émilien Delmont(Assistance Publique Hôpitaux de Marseille), Romaric Lacroix(Inserm), José Boucraut(Institut de Neurosciences des Systèmes), Ludivine Kouton(Hôpital de la Timone), Frédéric Vely(Centre National de la Recherche Scientifique), Laure Farnault(Aix-Marseille Université), John Boudjarane, Shahram Attarian(Aix-Marseille Université), Aude‐Marie Grapperon, Jean Gabert(Hôpital Nord), Étienne Fortanier(Laboratoire National de Référence)
Cited by 5
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
MIFlowCyt‐EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments
|Journal of Extracellular Vesicles|2020|514